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Multiple myeloma is a fatal plasma cell malignancy. New insights into its biology 
have identified mechanisms that have become molecular targets of so-called “new drugs” 
such as thalidomide, lenalidomide and bortezomib. The central role of high-dose therapy 
followed by autologous peripheral cell transplantation (AHCT), which remains a standard for 
younger and/or medically fit patients, has consequently evolved. Currently, cyto-reductive 
induction therapies before AHCT have incorporated several combinations of both the 
immunomodulatory derivatives thalidomide or, more recently, lenalidomide, and 
theproteasome inhibitor bortezomib. Though optimal combinations and treatment duration are 
a matter of debate, the use of these induction combinations has led to high response rates. 
Following the cyto-reduction obtained pre-transplant, AHCT can further improve depth of 
response. Patients younger than 65 years of age without relevant co-morbidities that 
contraindicate high-dose therapy are ideal candidates for AHCT. Though not all studies have 
uniformly reported the same advantages, randomized trials have demonstrated superior 
response rate and overall survival in patients treated with high dose therapy compared with 
conventional chemotherapy. 1 Whether single and double AHCT have similar outcomes 
remain to be determined.   
Before the introduction of new drugs, the combination vincristine-doxorubicin-
dexamethasone (VAD) and dexamethasone alone had been used for many years as pre-
transplant induction therapy. So called VAD-based regimen often became reference 
treatments in phase III study where toxicity and efficacy of new induction treatments, which 
incorporated new drugs as single agents, were first explored. Initially, a prospective phase III 
study compared thalidomide and dexamethasone (TD) with VAD and showed higher 
response rates after induction in the TD arm. However, the benefit was not confirmed 6 
months after autologous transplant, since very good partial response rates were almost 
identical. 2 Two randomized trials demonstrated that TD was better than high dose 
dexamethasone (HD) in terms of higher response rates and prolonged time to progression in 
patients treated with TD, but this did not translate into overall survival improvement. 3,4 Main 
toxicities related to thalidomide were deep vein thrombosis and peripheral neuropathy. In the 
light of these trials, the Food and Drug Administration (FDA) granted approval for TD for the 
treatment of newly diagnosed multiple myeloma. In 2 parallel German-Dutch phase III multi-
centre trials compared standard VAD regimen with TD plus doxorubicin (TAD): higher very 
good partial response rates after induction and after AHCT were observed with TAD.5 In a 
phase III study, the combination of bortezomib and dexametasone (VD) was compared with 
VAD as induction therapy before single or double AHCT. Importantly, in both arms, 
lenalidomide was given as consolidation/maintenance after AHCT. Response rates of at least 
very good partial response were significantly higher in the VD arm than in the VAD. An 
advantage was also maintained after the first and the second AHCT. However, the 
progression free survival did not reach statistical significance between the two arms. 6 
Lenalidomide with high-dose dexametasone (RD) was compared with lenalidomide and low-
dose dexamethasone (Rd) in a prospective control trial which included either eligible or 
ineligible patients for AHCT. Though response rate was significantly higher with RD 
compared with Rd, toxicity and early mortality were higher with RD. A landmark analysis 
showed that the 3-year overall survival of patients who received AHCT after RD or Rd was 
92% whereas in patients who did not receive AHCT was 79%.7 
The encouraging results of induction therapies with new drugs as single agents and 
preclinical findings, which showed that immunomodulatory drugs could increase the anti-
myeloma activity of bortezomib, formed the rational for combination therapies. Results of a 
phase III study of bortezomib-thalidomide-dexametasone (VTD) versus TD as induction 
therapy before and consolidation therapy after double AHCT have recently been reported. 8 
After three 21-day induction cycles, VTD was superior to TD in terms of response rates. 
Higher response rates in the VTD arm were also observed after two AHCT and subsequent 
consolidation therapy. The estimated 3-year PFS for the VTD group of patients was 
significantly longer than for those assigned to TD and double AHCT, 68% vs 56% 
respectively. Longer follow up is needed to possibly confirm a long-term survival advantage. 
In Total Therapy 3, VTD combined with cisplatin, doxorubicin, cyclophosphamide, and 
etoposide was given as induction therapy before and consolidation after double AHCT, while 
maintenance therapy with VTD was continued for one year after AHCT. Total Therapy 3 
significantly improved 2-year EFS and duration of complete remission as compared to Total 
Therapy 2 which associated TD with double AHCT. 9 A triplet combination of lenalidomide-
bortezomib-dexamethasone (RVD) has been explored in small series of newly diagnosed 
patients. 10,11 A phase I-II study on a series of 66 patients, who included eligible and ineligible 
patients for AHCT, received up to 8 cycles of RVD. Moreover, RVD maintenance was 
allowed in responding patients. After the first 4 cycles, the rates of at least near-complete 
remission and very good partial remission were 6% and 11%. Importantly, in about two thirds 
of the patients, deeper response was observed after the forth cycle and a further improvement 
was also reported during maintenance. 
 
The most common toxicities associated with thalidomide include constipation, 
somnolence, and peripheral neuropathy, frequently sensory or sensory-motor. Dose reduction 
or drug discontinuation commonly improves symptoms. By contrast, its analogue 
lenalidomide induces neutropenia and thrombocytopenia and only rarely peripheral 
neuropathy. Major clinical challenge of up-front treatment with these agents is the risk of 
thromboembolic complications. Prophylaxis guidelines have recently been proposed by the 
International Myeloma Working Group. 12 Peripheral neuropathy, primarily sensory, which 
may seriously impair quality of life, remains an important side effect during bortezomib 
treatment. To decrease incidence and severity, dose reduction, given on a twice-weekly basis, 
or once-weekly administration at a higher dose  have been proposed.  
 Overall, the proven clinical efficacy of these new agents, that target not only 
malignant plasma cells but also the myeloma microenvironment, does not currently allow to 
reach a cure. This provides the clinical rationale for using them in sequential approaches as 
induction before and as consolidation/maintenance after AHCT with the goal of converting 
the disease into a chronic phase that prolongs survival and improves quality of life. 
Consolidation treatment is designed to improve response following AHCT. Increase in 
response rates have been reported with the use of both bortezomib and lenalidomide. 
Moreover, some studies reported molecular remissions in a subset of patients. 13 Maintenance 
treatment as a means to prolong response duration and extend overall survival remains 
controversial. Recently, two independent phase III study indeed showed a longer progression 
free survival in patients treated with lenalidomide maintenance rather than placebo after 
single or double AHST. 14,15 However, concern has been risen by an unexpected incidence of 
second primary malignancies during lenalidomide treatment.   
 In summery, the incorporation of “new drugs” during induction therapy has practically 
become standard treatment in younger myeloma patients eligible for AHCT. 
Consolidation/maintenance therapy has resulted in longer progression free survival in several 
studies. However, convincing evidence that this will translate into a benefit in overall survival 
is lacking. Therefore, much longer follow up is needed to address this issue. At present, 
whether the recent advancements in myeloma treatment will eventually allow a cure remains 
unanswered.  
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